Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

831.00GBp
18 Mar 2019
Change (% chg)

0.00 (+0.00%)
Prev Close
831.00
Open
830.50
Day's High
833.00
Day's Low
830.00
Volume
1,318,145
Avg. Vol
2,305,620
52-wk High
853.00
52-wk Low
467.40

Select another date:

Wed, Jan 23 2019

UPDATE 1-Brazil's BTG seeks probe of XP for anti-competitive practices

SAO PAULO, Jan 22 Brazilian investment bank Banco BTG Pactual SA filed a complaint with the country's antitrust watchdog, Cade, accusing rival securities company XP Investimentos SA of anticompetitive practices and asking for an investigation, according to documents seen by Reuters.

Boston Scientific backs BTG offer with £3.3bn bridge loan

LONDON, Nov 21 (LPC) - US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn (US$4.22bn)bridge loan from Barclays Bank.

Boston Scientific backs BTG offer with £3.3bn bridge loan

LONDON, Nov 20 (LPC) - US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn bridge loan from Barclays Bank.

Boston Scientific builds medical technology with $4.2 billion BTG deal

LONDON U.S. medical device maker Boston Scientific Corp has agreed to buy Britain's BTG Plc for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio.

UPDATE 2-Boston Scientific builds medical tech with $4.2 billion BTG deal

* U.S. group's biggest deal since 2006 Guidant acquisition (Adds latest shares, analyst comment, further details)

Boston Scientific offers to buy UK's BTG for about $4.24 billion

Nov 20 U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash.

BTG Pharma upgrades sales guidance after strong first half

LONDON, Oct 4 British pharmaceutical firm BTG upgraded its sales forecast on Thursday after it included its varicose vein treatment Varithena in its oncology and vascular portfolio and saw strong demand for its tumour-targeting medicines.

Select another date: